Abstract
Challenges in social communication is one of the core symptom domains in autism spectrum disorder (ASD). Novel therapies are under development to help individuals with these challenges, however the ability to show a benefit is dependent on a sensitive and reliable measure of treatment effect. Currently, measuring these deficits requires the use of time-consuming and subjective techniques. Objective measures extracted from natural conversations could be more ecologically relevant, and administered more frequently – perhaps giving them added sensitivity to change. While several studies have used automated analysis methods to study autistic speech, they require manual transcriptions. In order to bypass this time-consuming process, an automated speaker diarization algorithm must first be applied. In this paper, we are testing whether a speaker diarization algorithm can be applied to natural conversations between autistic individuals and their conversational partner in a natural setting at home over the course of a clinical trial. We calculated the average duration that a participant would speak for within their turn. We found a significant correlation between this feature and the Vineland Adaptive Behaviour Scales (VABS) expressive communication score (r=0.51, p=7 × 10-5). Our results show that natural conversations can be used to obtain measures of talkativeness, and that this measure can be derived automatically, thus showing the promise of objectively evaluating communication challenges in ASD.
Index Terms speaker diarization, autism spectrum disorder, talkativeness, natural conversations, mean length of utterance
Competing Interest Statement
The authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: JOS, GB and JT are full-time contractors of F. Hoffmann-La Roche Ltd. WC, DS, PS, EE, TK, LM, ML, and FL are full-time employees of F. Hoffmann-La Roche Ltd. DN and JH are full-time employees and shareholders of F. Hoffmann-La Roche Ltd. CC is a full-time employee of Genentech, and a shareholder of F. Hoffmann-La Roche Ltd. NM does not possess any competing interests.
Funding Statement
This study was funded by F. Hoffmann-La Roche Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was obtained from all subjects and/or their legal guardian(s) (incase of minors). The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by Advarra IRB (Pro00035060, May 2018), BRANY IRB (#18-10-193-01, August 2018), Nathan Kline Institute for Psychiatric Research/Rockland Psychiatric Center IRB (1218792-12, August 2018), the Holland Bloorview Research Ethics Board (18-800, November 2018), the Wales Research Ethics Committee 5 Bangor (251572, September 2018), and the Western Institutional Review Board (20191384, August 2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Anonymized features are available upon reasonable request. Please contact Florian Lipsmeier: florian.lipsmeier{at}roche.com
